This study investigated the effect of bismuth shielding on thyroid dose and image quality in paediatric neck multidetector computed tomography (MDCT) performed with fixed tube current (FTC) and automatic exposure control (AEC). Four paediatric anthropomorphic phantoms representing the equivalent newborn, 1-, 5- and 10-y-old child were subjected to neck CT using a 16-slice MDCT system. Each scan was performed without and with single- and double-layered bismuth shield placed on the skin surface above the thyroid. Scans were repeated with cotton spacers of 1, 2 and 3 cm thick placed between the skin and shield, to study the effect of skin-to-shielding distance on image noise. Thyroid dose was measured with thermoluminescent dosemeters. The location of the thyroid within the phantom slices was determined by anthropometric data from patients' CT examinations whose body stature closely matched the phantoms. Effective dose (E) was estimated using the dose-length product (DLP) method. Image quality of resulted CT images was assessed through the image noise. Activation of AEC was found to decrease the thyroid dose by 46 % to the 10-y-old phantom subjected to neck CT. When FTC technique is used, single- and double-layered bismuth shielding was found to reduce the thyroid dose to the same phantom by 35 and 47 %, respectively. The corresponding reductions in AEC-activated scans were 60 and 66 %, respectively. Elevation of shields by 1-, 2- and 3-cm cotton spacers decreased the image noise by 69, 87 and 92 %, respectively, for single-layered FTC, without considerably affecting the thyroid dose. AEC was more effective in thyroid dose reduction than in-plane bismuth shields. Application of cotton spacers had no significant impact on thyroid dose, but significantly decreased the image noise.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/rpd/ncw007 | DOI Listing |
Clin Epidemiol
January 2025
Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Purpose: The thyroid gland is an organ at risk in breast cancer survivors who receive radiation therapy to the supraclavicular lymph nodes. We investigated the effect of radiation dose to the thyroid gland on the incidence of hypothyroidism in early-stage breast cancer patients treated with CT-guided radiation therapy.
Patients And Methods: We recruited women aged ≤75 years diagnosed with breast cancer from March 2016 through August 2017 at Odense University Hospital, Denmark.
BMJ Case Rep
January 2025
Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA
This case highlights that refractory pancytopenia leading to death can occur with methimazole treatment even at a very low cumulative dose and after a very short duration of exposure. In addition, the standard treatments to correct the pancytopenia may not be effective and a bone marrow transplant may be required. Current American Thyroid Association guidelines do not recommend routine monitoring of the complete blood count in patients receiving thionamides because of the rapidity of the onset of agranulocytosis and the lack of positive evidence that such monitoring would be useful.
View Article and Find Full Text PDFThe European Commission mandated EFSA to assess the toxicity of bromide, the existing maximum residue levels (MRLs), and possible transfer from feed into food of animal origin. The critical effects of bromide in experimental animals are on the thyroid and central nervous system. Changes in thyroid hormone homeostasis could result in neurodevelopmental toxicity, among other adverse effects.
View Article and Find Full Text PDFCancer
February 2025
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, Maryland, USA.
Tarlatamab is a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation 3 (CD3) molecule. In the phase 2 DeLLphi-301 trial of tarlatamab for patients with previously treated small cell lung cancer, tarlatamab 10 mg every 2 weeks achieved durable responses and encouraging survival outcomes. Analyses of updated safety data from the DeLLphi-301 trial demonstrated that the most common treatment-emergent adverse events were cytokine release syndrome (53%), pyrexia (38%), decreased appetite (36%), dysgeusia (32%), and an emia (30%).
View Article and Find Full Text PDFBMC Cancer
January 2025
Department of Radiation Oncology, First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, 650032, P. R. China.
Introduction: The core objective of this study was to precisely locate metastatic lymph nodes, identify potential areas in nasopharyngeal carcinoma patients that may not require radiotherapy, and propose a hypothesis for reduced target volume radiotherapy on the basis of these findings. Ultimately, we reassessed the differences in dosimetry of organs at risk (OARs) between reduced target volume (reduced CTV2) radiotherapy and standard radiotherapy.
Methods And Materials: A total of 209 patients participated in the study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!